Telix Pharmaceuticals (TLPPF) Other Non-Current Assets (2023 - 2026)

Telix Pharmaceuticals (TLPPF) has reported Other Non-Current Assets for 4 consecutive years, with $33.9 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Other Non-Current Assets changed N/A year-over-year to $33.9 million in Q2 2026; TTM through Jun 2026 was $33.9 million, a N/A change from a year earlier, with the FY2025 full-year figure at $28.8 million, down 89.34% from the prior year.
• Other Non-Current Assets was $33.9 million for Q2 2026 at Telix Pharmaceuticals, up from $28.8 million in the prior quarter.
• Over five years, Other Non-Current Assets peaked at $33.9 million in Q2 2026 and troughed at $381480.4 in Q4 2023.
• A 4-year average of $19.8 million and a median of $22.5 million in 2024 frame the typical range for Other Non-Current Assets.
• Across the five-year window, Other Non-Current Assets surged 4113.99% in 2024 and jumped 79.31% in 2025, its largest moves.
• Over 4 years, Other Non-Current Assets stood at $381480.4 in 2023, then surged by 4113.99% to $16.1 million in 2024, then jumped by 79.31% to $28.8 million in 2025, then climbed by 17.55% to $33.9 million in 2026.
• The last three Other Non-Current Assets figures came in at $33.9 million (Q2 2026), $28.8 million (Q4 2025), and $16.1 million (Q4 2024), per Business Quant data.